PE20200333A1 - Compuestos y metodos para tratar infecciones bacterianas - Google Patents

Compuestos y metodos para tratar infecciones bacterianas

Info

Publication number
PE20200333A1
PE20200333A1 PE2019002309A PE2019002309A PE20200333A1 PE 20200333 A1 PE20200333 A1 PE 20200333A1 PE 2019002309 A PE2019002309 A PE 2019002309A PE 2019002309 A PE2019002309 A PE 2019002309A PE 20200333 A1 PE20200333 A1 PE 20200333A1
Authority
PE
Peru
Prior art keywords
compounds
methods
bacterial infections
treat bacterial
alkyl
Prior art date
Application number
PE2019002309A
Other languages
English (en)
Spanish (es)
Inventor
Janelle Comita-Prevoir
Thomas Francois Durand-Reville
Satenig Guler
Jan Romero
Mark Sylvester
Ruben Tommasi
Camilo Velez-Vega
Xiaoyun Wu
Jing Zhang
Original Assignee
Entasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entasis Therapeutics Inc filed Critical Entasis Therapeutics Inc
Publication of PE20200333A1 publication Critical patent/PE20200333A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PE2019002309A 2017-05-08 2018-05-08 Compuestos y metodos para tratar infecciones bacterianas PE20200333A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762502867P 2017-05-08 2017-05-08
PCT/US2018/031593 WO2018208769A1 (en) 2017-05-08 2018-05-08 Compounds and methods for treating bacterial infections

Publications (1)

Publication Number Publication Date
PE20200333A1 true PE20200333A1 (es) 2020-02-14

Family

ID=62223332

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019002309A PE20200333A1 (es) 2017-05-08 2018-05-08 Compuestos y metodos para tratar infecciones bacterianas

Country Status (27)

Country Link
US (1) US11046694B2 (enExample)
EP (1) EP3630111B1 (enExample)
JP (1) JP7058322B2 (enExample)
KR (1) KR102611447B1 (enExample)
CN (1) CN110709081B (enExample)
AU (1) AU2018266640B2 (enExample)
CA (1) CA3059773A1 (enExample)
CY (1) CY1125340T1 (enExample)
DK (1) DK3630111T3 (enExample)
EA (1) EA038393B1 (enExample)
ES (1) ES2907858T3 (enExample)
HR (1) HRP20220231T1 (enExample)
HU (1) HUE057592T2 (enExample)
IL (1) IL270380B (enExample)
LT (1) LT3630111T (enExample)
MA (1) MA48743A (enExample)
MX (1) MX385203B (enExample)
MY (1) MY201377A (enExample)
PE (1) PE20200333A1 (enExample)
PH (1) PH12019502509A1 (enExample)
PL (1) PL3630111T3 (enExample)
PT (1) PT3630111T (enExample)
SG (1) SG11201909443YA (enExample)
SI (1) SI3630111T1 (enExample)
SM (1) SMT202200110T1 (enExample)
TW (1) TWI791018B (enExample)
WO (1) WO2018208769A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3833665T3 (fi) 2018-08-09 2023-10-09 Antabio Sas Diatsabisyklo-oktanoneja seriini-beeta-laktamaasien inhibiittoreina
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
CN111675641B (zh) * 2020-06-04 2023-09-08 宁夏农林科学院农业资源与环境研究所(宁夏土壤与植物营养重点实验室) 单环β-内酰胺类化合物、单环内酰胺类化合物盐及其制备方法
CN115605480B (zh) 2021-05-07 2024-04-05 宁夏农林科学院 磺酰脒取代的化合物及其作为β-内酰胺酶抑制剂的用途
US11814385B2 (en) 2021-06-25 2023-11-14 University Of South Florida Small molecule inhibitors targeting Clostridioides difficile sporulation
WO2025064681A1 (en) * 2023-09-19 2025-03-27 Entasis Therapeutics Inc. Compounds and methods for treating bacterial infections

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69416869T2 (de) 1993-12-29 1999-07-01 Pfizer Inc., New York, N.Y. Diazabicyclische neurokinin antagonisten
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
FR2848210B1 (fr) * 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
US7507727B2 (en) * 2003-04-07 2009-03-24 Cylene Pharmaceuticals, Inc. Substituted quinobenzoxazine analogs and methods of using thereof
FR2914923B1 (fr) 2007-04-12 2013-06-14 Novexel Nouveaux composes heterocycliques azotes,leur preparation et leur utilisation comme medicaments antibacteriens.
PL2231667T3 (pl) 2008-01-18 2014-01-31 Merck Sharp & Dohme Inhibitory beta-laktamazy
FR2930553B1 (fr) 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
EP2921559A1 (en) 2008-06-19 2015-09-23 Astra Zeneca Holding France Use of (1r,2s,5r) 1,6-diazabicyclo [3.2.1]octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases
FR2936798B1 (fr) 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2937034B1 (fr) * 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
FR2936951B1 (fr) 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
CN103687598B (zh) 2011-07-26 2016-03-16 沃克哈特有限公司 包括舒巴坦和β-内酰胺酶抑制剂的药物组合物
EP2768503A1 (en) 2011-07-26 2014-08-27 Wockhardt Limited Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor
EP2748165B1 (en) 2011-08-27 2016-11-02 Wockhardt Limited 1,6-diazabicyclo[3,2,1]octan-7-one derivatives and their use in the treatment of bacterial infections.
US9006230B2 (en) * 2011-08-30 2015-04-14 Wockhardt Ltd. 1,6-diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections
ES2640520T3 (es) 2011-09-13 2017-11-03 Wockhardt Limited Compuestos que contienen nitrógeno y su uso
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
WO2013122888A2 (en) 2012-02-15 2013-08-22 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
TW201343646A (zh) 2012-03-30 2013-11-01 Cubist Pharm Inc 異□唑β-內醯胺酶抑制劑
US8916709B2 (en) * 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
US8933232B2 (en) 2012-03-30 2015-01-13 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors
AR090539A1 (es) 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
CN104334559B (zh) 2012-05-30 2017-03-22 明治制果药业株式会社 β‑内酰胺酶抑制剂及其制备方法
AU2013308127B2 (en) 2012-08-25 2015-08-13 Wockhardt Limited 1,6- Diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections
CN104768547A (zh) 2012-09-03 2015-07-08 沃克哈特有限公司 抗菌组合物
CA2897446A1 (en) 2013-02-06 2014-08-14 Astrazeneca Ab Combination therapy for the treatment of nosocomial pneumonia
WO2014141132A1 (en) * 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
ME03357B (me) 2014-11-17 2019-10-20 Entasis Therapeutics Ltd Kombinovana terapija za lečenje rezistentnih bakterijsкih infekcija
KR102537340B1 (ko) 2016-09-16 2023-05-26 엔타시스 테라퓨틱스 리미티드 베타-락타마제 억제제 화합물

Also Published As

Publication number Publication date
KR102611447B1 (ko) 2023-12-06
ES2907858T3 (es) 2022-04-26
IL270380B (en) 2022-06-01
EP3630111B1 (en) 2021-11-24
EP3630111A1 (en) 2020-04-08
WO2018208769A1 (en) 2018-11-15
CA3059773A1 (en) 2018-11-15
MX2019013291A (es) 2020-01-15
PH12019502509A1 (en) 2020-07-13
BR112019023130A2 (pt) 2020-05-26
CY1125340T1 (el) 2024-02-16
MY201377A (en) 2024-02-21
US11046694B2 (en) 2021-06-29
HUE057592T2 (hu) 2022-05-28
JP2020519687A (ja) 2020-07-02
KR20200005586A (ko) 2020-01-15
MA48743A (fr) 2020-04-08
MX385203B (es) 2025-03-14
US20200165251A1 (en) 2020-05-28
CN110709081B (zh) 2023-09-22
PT3630111T (pt) 2022-03-01
EA038393B1 (ru) 2021-08-20
DK3630111T3 (en) 2022-03-14
SG11201909443YA (en) 2019-11-28
SI3630111T1 (sl) 2022-05-31
AU2018266640B2 (en) 2022-03-03
SMT202200110T1 (it) 2022-05-12
TW201843152A (zh) 2018-12-16
AU2018266640A1 (en) 2019-11-07
TWI791018B (zh) 2023-02-01
JP7058322B2 (ja) 2022-04-21
PL3630111T3 (pl) 2022-05-23
LT3630111T (lt) 2022-03-10
HRP20220231T1 (hr) 2022-04-29
EA201992370A1 (ru) 2020-03-10
CN110709081A (zh) 2020-01-17

Similar Documents

Publication Publication Date Title
PE20200333A1 (es) Compuestos y metodos para tratar infecciones bacterianas
MX2022005839A (es) Compuestos utiles como inhibidores de la proteina helios.
ECSP20044709A (es) Inhibidores de sarcómero cardíaco
CR20170605A (es) DERIVADOS DE 3-TETRAZOLIL-BENCENO-1,2-DISULFONAMIDA COMO INHIBIDORES DE METALO -ß-LACTAMASA
MX392515B (es) Compuestos inhibidores de beta-lactamasa
NI202000023A (es) Compuestos monobactámicos cromanos para el tratamiento de infecciones bacterianas.
MX2018005382A (es) Compuestos de biaril-monobactam y metodos de uso de los mismos para el tratamiento de infecciones bacterianas.
CO2023013321A2 (es) Compuestos de oxoisoindolina sustituidos con piridinilo
AR053120A1 (es) Aminopiridinas como inhibidores de beta secretasa
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
PE20180412A1 (es) Compuestos inhibidores de la senalizacion de la via de notch
CO2019004978A2 (es) Compuestos terapéuticos y métodos para utilizarlos
MX2020003383A (es) Compuesto de griseofulvina y uso farmacéutico de este.
ECSP21011232A (es) Nuevo derivado de amina heterocíclico y composición farmacéutica que lo comprende
MX2020000576A (es) Compuestos quimicos.
CO2019013254A2 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
DOP2024000096A (es) Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
MX2020001412A (es) Compuestos y métodos para tratar la hiperpotasemia.
MX2020008706A (es) Nuevos compuestos de opioides y sus usos.
AR131945A1 (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno
EA202090357A1 (ru) Химические соединения
EA202190585A1 (ru) Производные индана для применения при лечении бактериальной инфекции
EA201591697A1 (ru) Гидрохлоридные соли антибиотического соединения
TH1701007800A (th) ตัวยับยั้งเมทัลโล-บีตา-แลคทาเมส
EA202190444A1 (ru) Диазабициклооктаноны в качестве ингибиторов сериновых бета-лактамаз